See more : LS 1x Facebook Tracker ETP (FB1.L) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Covestro AG (1COV.DE) Income Statement Analysis – Financial Results
- Urbana Corporation (URB-A.TO) Income Statement Analysis – Financial Results
- Shenzhen Universe Group Co., Ltd. (000023.SZ) Income Statement Analysis – Financial Results
- WPD Pharmaceuticals Inc. (WPDPF) Income Statement Analysis – Financial Results
- Sun Pacific Holding Corp. (SNPW) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy Bio stops enrolling patients in blood cancer therapy study
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
Source: https://incomestatements.info
Category: Stock Reports